Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia (DAPTO-SNAP)

Todd C. Lee MD MPH FIDSA

Status and phase: Enrolling; Phase 4

Conditions: S. Aureus Bacteremia; Staphylococcus Aureus Septicemia; Staphylococcus Aureus Endocarditis; S. Aureus Bloodstream Infection; Staphylococcus Aureus Bacteremia

Treatments: Drug: Daptomycin for Injection; Drug: Vancomycin (IV)

Study type: Interventional

Funder types: Other

Identifiers

NCT06637332

466322 (Other Grant/Funding Number)

2025-10666

Details and patient eligibility

About

This is an open label randomized controlled trial for patients with methicillin resistant S. aureus (MRSA) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin.

This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)

Enrollment: 300 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

The participant must meet all inclusion and exclusion criteria for the SNAP Platform (NCT05137119) and also the following inclusion and exclusion criteria:

Inclusion Criteria:

• Methicillin-resistant S. aureus bacteremia

Exclusion Criteria:

• Severe allergy or non-severe rash to vancomycin or daptomycin
• Suspected or confirmed MRSA pneumonia
• Known vancomycin minimum inhibitory concentration (MIC) greater than or equal to 2mg/L or daptomycin MIC greater than or equal to 1mg/L

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

300 participants in 2 patient groups

Daptomycin

Experimental group

Description:

Daptomycin given by injection at a dose determined by the treating clinicians but no less than 6mg/kg

Treatment:

Drug: Daptomycin for Injection

Vancomycin

Active Comparator group

Description:

Vancomycin given by injection at a dose determined by the treating clinicians to achieve a trough-based or AUC-based target

Treatment:

Drug: Vancomycin (IV)